In earlier methionine studies (1), it was noted that the fasting plasma methionine 4 levels in some patients with acute and chronic liver disease, receiving DL-methionine, tended to be markedly increased. It was not too clear in all instances whether this elevation related to the methionine administration, to the disease process, or to a combination of the two. It was definite, however, that severe liver disease in itself could account for some elevation of the fasting plasma methionine level. Over an 11-month period we have attempted further to clarify this picture.
In earlier methionine studies (1) , it was noted that the fasting plasma methionine 4 levels in some patients with acute and chronic liver disease, receiving DL-methionine, tended to be markedly increased. It was not too clear in all instances whether this elevation related to the methionine administration, to the disease process, or to a combination of the two. It was definite, however, that severe liver disease in itself could account for some elevation of the fasting plasma methionine level. Over an 11-month period we have attempted further to clarify this picture.
PROCEDURES
The actual quantitative assay procedures have been previously described (2, 3) . It might be emphasized here that one concept held earlier has been modified in that the normal fasting plasma methionine level varies within a very narrow range, from 0.25 mgm. per 100 cc. to 0.48 mgm. per 100 cc., with a mean of 0.33 mgm. per 100 cc. The previous concept of a wider normal range related to a longer period intervening between the obtaining of the blood sample and the preparation of the protein-free filtrate. Considerable proteolysis apparently occurs in a matter of a few hours in some plasma specimens. All determinations here reported have been performed on protein-free filtrates prepared within three hours from the time of withdrawal of blood.
The first patients and controls in this series were given 3 gms. of DL-methionine three times daily by mouth as compressed 0.5 gm. tablets, over During this entire period of study, the patients were subjected to careful daily clinical evaluation by different members of the staff in order to detect any observable changes which might relate to the duration of methionine administration and the plasma level of methionine.
This procedure was found to be unsatisfactory for serial studies in patients with acute viral hepatitis. Such individuals have therefore received 9 gms. of methionine daily for two-day periods, at intervals during the course of their disease. The evaluation of the periods preceding and following methionine administration has been correspondingly shortened.
For purposes of description, comparison, and evaluation, the patients have been divided into arbitrary diagnostic categories (see below).
CHEMICAL EVALUATION
Normal Controls (Figure 1) Six control studies have been obtained in five young adult males. In control subject MAR, two studies were conducted-one on an average diet (essentially the same type of diet as supplied to all other controls) and the second on an 800-calorie, relatively high-protein diet. This latter study was carried out because of a question as to whether the abnormal values noted in patients with liver damage might refer to the relatively poor dietary intake of one or two of the patients studied in the early phase of this investigation. As will be seen from the data which follow, there are no significant differences in methionine retention in this normal man while on the 800-calorie diet as compared to an average isocaloric diet.
Fasting Plasma Methionine Levels L-methionine 1. Prior to methionine administration: All values were in the normal range previously noted.
2. During methionine administration: Elevation of the fasting level was noted in the first 24 hours in all subjects. In no normal man was a value noted in excess of 2 mgm. per 100 cc. at any time during the period of methionine administration.
3. Following methionine administration: A fall to normal levels was noted within 24-48 hours after the cessation of methionine administration in all normal control subjects. D-methionine 1. Prior to methionine ingestion: Within the limits of the method, no D-methionine was found in any instance in the pre-treatment state.
2. During methionine ingestion: An elevation of the fasting plasma D-methionine was noted in all control subjects within the first 24 hours. Maximal values were 1.92, 2.54, 0.62, 2.39, 2.35 and 2.11 mgm. per 100 cc., respectively.
3. Following methionine ingestion: Except for the control subject MIC, all values returned to essentially zero within 24 hours after the cessation of the methionine. Serial studies on two representative patients are shown using a short (two-day methionine administration) program for the reasons previously noted. The relationship between the status of the disease, as shown by the presence of icterus, and the degree of methionine retention is obvious. In these and other similar patients, the cephalin cholesterol flocculation and the methionine retention procedures were usually the last of a panel of liver function tests (which included the determination of bromsulfalein retention, free and combined bilirubin, and prothrombin time) to become normal.
Patients with Chronic Viral Hepatitis (Figure 3)
Studies in three patients are presented. All had histories compatible with an attack of acute viral hepatitis one and one-half or more years before this study was undertaken. All have been extensively studied from the standpoint of liver func- .0 On July 9, 1948 he was placed on 9 gms. of DL-methionine daily. By July 27 he had become obviously toxic, the toxicity including some degree of disorientation and a penetrating odor which was not entirely that of methionine and which suggested the so-called "hepatic fetor." The same dose of methionine, that is, 9 gms. daily, was continued until the 2nd of August, 1948. From July 21 until August 2, he also received 9 gms. of choline chloride daily. The first methionine value shown in Study No. 1 in this patient was obtained on July 21, that is, 12 days after the institution of methionine in a dose of 9 gms. daily, and on the first day of choline chloride administration.
The second methionine study was carried on as part of a protein balance study and was instituted on October 11, 1948. His liver function tests at this time were still significantly abnormal although he no longer had any detectable ascites. The initial portion of the second study was interrupted because of the appearance of symptoms which were attributed to salt deprivation referable to a period of hot weather and low-sodium intake. When this condition was corrected the study was resumed with the results shown in Figure 3 . During this second period of methionine administration, he again manifested the symptoms of major and progressive mental clouding coupled with a strong fetor which was similar to, but probably not identical with that which is commonly called fetor hepaticus.
Following the completion of this balance study, the patient was permitted to return home and was instructed to come in for a further evaluation after the Christmas holidays. Unhappily, he had a fatal hemorrhage from esophageal varices about one month after leaving this hospital and his local physician obtained no postmortem examination.
The deviations from normal of the fasting plasma L-methionine values in all three patients are quite definite, and in the last two are most striking. The degree of abnormality would appear to parallel the severity of the disease process. It is also apparent that increased urinary L-methionine appears in those individuals with very high plasma levels. These patients received the usual therapy for* this disease, that is to say, a high-protein, highvitamin, adequate-calorie diet with supplemental choline chloride and with complete bed rest during the first several weeks of treatment. Routine liver function tests, which initially were abnormal in both men, became progressively more normal; and in Patient DOH, at the time of the second study shown in Figure 4 , had all become normal except for slight elevation of the serum globulin and 3 + cephalin flocculation.
As in the patients with chronic viral liver damage, it appears that the degree of elevation of the fasting plasma L-methionine, under these conditions, bears some relation to the degree of hepatic At the time of his initial study, he was far along on the road to convalescence, having a barely palpable liver, no residual ascites, and clinically no complaints whatever. His other liver function tests at this time were normal. The methionine retention study showed a plasma L-methionine level which was within normal limits throughout. There was, however, a very marked elevation of the plasma D-methionine, a maximal level of 16.16 mgm. per 100 cc. being attained on the 11th day of methionine administration, together with most impressive elevation throughout. On the fourth day post-methionine, the plasma D-methionine was still elevated, the level being 0.95 mgm. per 100 cc. Evaluation of the urinary methionine levels showed a single peak excretion on the second three-day period during methionine administration, the level reaching 115.5 mgm. per hour, but at all other times the D-methionine excretion was so low as to approach the limits of accuracy of the procedure. From this observatio* we postulated that the mechanism of the entire picture related to some intrinsic renal defect which caused this man to reabsorb D-methionine at the same rate at which he normally would reabsorb L-methionine.
One month later the procedure was repeated in an identical fashion. The plasma D-methionine and L-methionine levels, as will be seen from Figure 5 , were not significantly different from that noted in the first studies, but the urinary Dmethionine values were of a high rather than low magnitude on this occasion. Urinary L-methionine was minimal throughout both studies. During these two periods of methionine administration he manifested symptoms and findings which may be referable to methionine toxicity; namely, a progressive anorexia coupled with malaise and with a strong fetor approximating that noted in the patients previously described. There was no major degree of disorientation, however, as was observed in Patient CUN (Figure 3 severe liver disease has a high fasting plasma methionine level without previous methionine administration. The abnormality in methionine metabolism in the patient with mild or moderate liver damage is only apparent when stress is applied. In our experience thus far, a spontaneously high fasting level is always correlated with a prolonged, difficult convalescence, whether the disease be viral hepatitis or "cirrhosis."
The possible mechanisms of impairment in methionine utilization provide material for speculation. Three metabolic pathways are normally open: (1) Incorporation of the methionine into protein tissue; (2) demethylation with resultant homocysteine formation; and (3) oxidation of the methionine molecule with resultant excretion of the oxidized sulfur as urinary inorganic sulfate. It appears probable that the block occurs in (1) or (2) , inasmuch as the excretion of urinary sulEate is considerably increased in 'some of the patients with high plasma methionine levels. Simultaneous quantitation of plasma cysteine will help to rule in or out the presence of block in the methionine --homocysteine -> cysteine sequence.
Such studies are under way at the present time.
Also in the process of evaluation is the determination of methionine utilization in patients with non-hepatic disease. Should a high degree of specificity for liver disease be found, it is conceivable that the procedure may have some clinical applicability.
The appearance of a reproducible picture of toxicity in patients whose ability to utilize methionine is impaired, suggests the need for caution in the indiscriminate use of this material as a therapeutic agent in individuals with liver disease. It is probably best to regard dietary methionine as the logical source of the amino acid in such patients.
SUMMARY
Daily administration of 9 gms. of DL-methionine to patients with liver damage results in a significant elevation of the fasting plasma L-methionine, as compared to normal controls; such abnormal retention disappears when the hepatic status reverts to normal.
